Lashilola, Seun
Xu, Weiwei
Azimpour, Khashayar
McCarthy, Michael
Carlot, Sara
Game, David
van der Voort, Judith
Funding for this research was provided by:
Chiesi Foundation
Article History
Received: 17 November 2022
Accepted: 8 November 2023
First Online: 29 November 2023
Declarations
:
: This study is a cost analysis conducted in line with the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) [CitationRef removed] Statement (supplementary materials). This study is based on publicly available data. No ethical approval was required.
: Not applicable.
: KA, and SC are employees of Chiesi Farmaceutici. SL and WX are employees of IQVIA, that received consulting fees from Chiesi Farmaceutici. At the time of writing, MM was an employee of MAP Patient Access who received consulting fees from Chiesi Farmaceutici. DG and JV are nephrologists at Guy’s Hospital in London, and University Hospital of Wales, respectively; they received consulting fees from Chiesi Farmaceutici.